Customize your JAMA Network experience by selecting one or more topics from the list below.
Copyright 2016 American Medical Association. All Rights Reserved.
In the Original Investigation titled “Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial,” published in the September issue of JAMA Otolaryngology–Head & Neck Surgery,1 incorrect values for the numbers of patients at risk appeared in Figure 2A. At day 30, the numbers of patients at risk should be 34 for CRT (cetuximab plus radiotherapy) and 25 for radiotherapy alone (not 3 and 2). This article was corrected online.
Incorrect Numbers at Risk in Figure. JAMA Otolaryngol Head Neck Surg. 2017;143(1):97. doi:10.1001/jamaoto.2016.4352
Create a personal account or sign in to: